(AMPH) Amphastar P - Overview
Stock: Injectable, Inhalation, Intranasal, Emergency, Hormone
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 42.1% |
| Relative Tail Risk | -6.17% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.15 |
| Alpha | -23.62 |
| Character TTM | |
|---|---|
| Beta | 0.758 |
| Beta Downside | 0.598 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.28% |
| CAGR/Max DD | -0.04 |
Description: AMPH Amphastar P January 19, 2026
Amphastar Pharmaceuticals (NASDAQ: AMPH) is a U.S.-based biopharma that focuses on injectable, inhalation, and intranasal medicines. Its commercial portfolio includes the nasal-spray BAQSIMI for severe hypoglycemia, the OTC epinephrine inhaler Primatene Mist for mild asthma, and a suite of emergency-use injectables such as Enoxaparin, Naloxone, Glucagon, and Cortrosyn. The company also markets specialty injectables (e.g., Amphadase hyaluronidase, lidocaine formulations, vitamin K1, morphine, lorazepam) and a range of niche products for cardiovascular, endocrine, and reproductive indications, while maintaining a pipeline of generics, biosimilars, and an intranasal epinephrine candidate.
In Q3 2024 Amphastar reported net revenue of $78 million, a 12 % YoY increase driven primarily by higher sales of BAQSIMI and expanded distribution of Primatene Mist after its OTC transition. The balance sheet shows $102 million in cash and equivalents, providing runway for its upcoming generic Enoxaparin launch and the Phase III study of an intranasal epinephrine product. Key sector dynamics include an aging U.S. population that raises demand for injectable emergency therapies, and ongoing pressure on generic pricing that makes market access and cost-efficiency critical success factors.
For a deeper, data-rich view of Amphastar’s valuation and risk profile, you may find the ValueRay analysis worth a quick look.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 111.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -4.21 > 1.0 |
| NWC/Revenue: 60.04% < 20% (prev 53.66%; Δ 6.38% < -1%) |
| CFO/TA 0.09 > 3% & CFO 152.3m > Net Income 111.6m |
| Net Debt (440.3m) to EBITDA (221.2m): 1.99 < 3 |
| Current Ratio: 3.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.7m) vs 12m ago -8.07% < -2% |
| Gross Margin: 49.36% > 18% (prev 0.53%; Δ 4883 % > 0.5%) |
| Asset Turnover: 45.05% > 50% (prev 46.67%; Δ -1.63% > 0%) |
| Interest Coverage Ratio: 6.37 > 6 (EBITDA TTM 221.2m / Interest Expense TTM 25.3m) |
Altman Z'' 4.39
| A: 0.26 (Total Current Assets 639.5m - Total Current Liabilities 205.2m) / Total Assets 1.67b |
| B: 0.39 (Retained Earnings 642.5m / Total Assets 1.67b) |
| C: 0.10 (EBIT TTM 160.9m / Avg Total Assets 1.61b) |
| D: 0.72 (Book Value of Equity 637.2m / Total Liabilities 889.5m) |
| Altman-Z'' Score: 4.39 = AA |
Beneish M -3.02
| DSRI: 1.01 (Receivables 146.8m/145.0m, Revenue 723.3m/721.2m) |
| GMI: 1.07 (GM 49.36% / 52.77%) |
| AQI: 0.93 (AQ_t 0.40 / AQ_t-1 0.43) |
| SGI: 1.00 (Revenue 723.3m / 721.2m) |
| TATA: -0.02 (NI 111.6m - CFO 152.3m) / TA 1.67b) |
| Beneish M-Score: -3.02 (Cap -4..+1) = AA |
What is the price of AMPH shares?
Over the past week, the price has changed by +10.46%, over one month by +5.94%, over three months by +20.76% and over the past year by -10.77%.
Is AMPH a buy, sell or hold?
- StrongBuy: 2
- Buy: 0
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the AMPH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 31.6 | 7.9% |
| Analysts Target Price | 31.6 | 7.9% |
| ValueRay Target Price | 28.4 | -3% |
AMPH Fundamental Data Overview February 03, 2026
P/S = 1.7028
P/B = 1.5683
P/EG = 2.77
Revenue TTM = 723.3m USD
EBIT TTM = 160.9m USD
EBITDA TTM = 221.2m USD
Long Term Debt = 608.6m USD (from longTermDebt, last quarter)
Short Term Debt = 8.75m USD (from shortTermDebt, last quarter)
Debt = 656.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 440.3m USD (from netDebt column, last quarter)
Enterprise Value = 1.61b USD (1.23b + Debt 656.8m - CCE 278.6m)
Interest Coverage Ratio = 6.37 (Ebit TTM 160.9m / Interest Expense TTM 25.3m)
EV/FCF = 14.21x (Enterprise Value 1.61b / FCF TTM 113.3m)
FCF Yield = 7.04% (FCF TTM 113.3m / Enterprise Value 1.61b)
FCF Margin = 15.66% (FCF TTM 113.3m / Revenue TTM 723.3m)
Net Margin = 15.43% (Net Income TTM 111.6m / Revenue TTM 723.3m)
Gross Margin = 49.36% ((Revenue TTM 723.3m - Cost of Revenue TTM 366.3m) / Revenue TTM)
Gross Margin QoQ = 51.42% (prev 49.59%)
Tobins Q-Ratio = 0.97 (Enterprise Value 1.61b / Total Assets 1.67b)
Interest Expense / Debt = 0.96% (Interest Expense 6.28m / Debt 656.8m)
Taxrate = 19.35% (4.16m / 21.5m)
NOPAT = 129.8m (EBIT 160.9m * (1 - 19.35%))
Current Ratio = 3.12 (Total Current Assets 639.5m / Total Current Liabilities 205.2m)
Debt / Equity = 0.85 (Debt 656.8m / totalStockholderEquity, last quarter 776.7m)
Debt / EBITDA = 1.99 (Net Debt 440.3m / EBITDA 221.2m)
Debt / FCF = 3.89 (Net Debt 440.3m / FCF TTM 113.3m)
Total Stockholder Equity = 754.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.95% (Net Income 111.6m / Total Assets 1.67b)
RoE = 14.80% (Net Income TTM 111.6m / Total Stockholder Equity 754.5m)
RoCE = 11.81% (EBIT 160.9m / Capital Employed (Equity 754.5m + L.T.Debt 608.6m))
RoIC = 9.54% (NOPAT 129.8m / Invested Capital 1.36b)
WACC = 5.95% (E(1.23b)/V(1.89b) * Re(8.71%) + D(656.8m)/V(1.89b) * Rd(0.96%) * (1-Tc(0.19)))
Discount Rate = 8.71% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -5.17%
[DCF Debug] Terminal Value 87.92% ; FCFF base≈136.0m ; Y1≈161.7m ; Y5≈252.8m
Fair Price DCF = 148.6 (EV 7.27b - Net Debt 440.3m = Equity 6.83b / Shares 46.0m; r=5.95% [WACC]; 5y FCF grow 20.13% → 2.90% )
EPS Correlation: 76.44 | EPS CAGR: 23.61% | SUE: 0.47 | # QB: 0
Revenue Correlation: 90.10 | Revenue CAGR: 13.11% | SUE: 1.22 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.79 | Chg30d=-0.011 | Revisions Net=-1 | Analysts=4
EPS next Year (2026-12-31): EPS=3.56 | Chg30d=-0.127 | Revisions Net=-1 | Growth EPS=+5.4% | Growth Revenue=+4.8%